NCT02870400View on ClinicalTrials.gov

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

January 12, 2017

Study Completion Date

January 12, 2017

Conditions
Healthy Volunteers
Interventions
DRUG

REGN2477

Participants will receive ascending doses of REGN2477

DRUG

Placebo

Participants will receive matching placebo

Trial Locations (1)

Unknown

Antwerp

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02870400 - A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477 | Biotech Hunter | Biotech Hunter